International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. by Schijman, Alejandro G et al.
Schijman, AG; Bisio, M; Orellana, L; Sued, M; Duffy, T; Jaramillo,
AMM; Cura, C; Auter, F; Veron, V; Qvarnstrom, Y; Deborggraeve,
S; Hijar, G; Zulantay, I; Lucero, RH; Velazquez, E; Tellez, T; Leon,
ZS; Galvao, L; Nolder, D; Rumi, MM; Levi, JE; Ramirez, JD; Zorrilla,
P; Flores, M; Jercic, MI; Crisante, G; Anez, N; Castro, AM; Gon-
zalez, CI; Viana, KA; Yachelini, P; Torrico, F; Robello, C; Diosque,
P; Chavez, OT; Aznar, C; Russomando, G; Buscher, P; Assal, A;
Guhl, F; Estani, SS; Dasilva, A; Britto, C; Luquetti, A; Ladzins, J
(2011) International Study to Evaluate PCR Methods for Detection
of Trypanosoma cruzi DNA in Blood Samples from Chagas Disease
Patients. PLoS neglected tropical diseases, 5 (1). ISSN 1935-2727
DOI: 10.1371/journal.pntd.0000931
Downloaded from: http://researchonline.lshtm.ac.uk/1294/
DOI: 10.1371/journal.pntd.0000931
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
International Study to Evaluate PCR Methods for
Detection of Trypanosoma cruzi DNA in Blood Samples
from Chagas Disease Patients
Alejandro G. Schijman1*, Margarita Bisio1, Liliana Orellana2, Mariela Sued2, Toma´s Duffy1, Ana M. Mejia
Jaramillo3, Carolina Cura1, Frederic Auter4, Vincent Veron5, Yvonne Qvarnstrom6, Stijn Deborggraeve7,
Gisely Hijar8, Ine´s Zulantay9, Rau´l Horacio Lucero10, Elsa Velazquez11, Tatiana Tellez12, Zunilda Sanchez
Leon13, Lucia Galva˜o14, Debbie Nolder15, Marı´a Monje Rumi16, Jose´ E. Levi17, Juan D. Ramirez18, Pilar
Zorrilla19, Marı´a Flores20, Maria I. Jercic21, Gladys Crisante22, Ne´stor An˜ez22, Ana M. De Castro23, Clara I.
Gonzalez24, Karla Acosta Viana25, Pedro Yachelini26, Faustino Torrico12, Carlos Robello19, Patricio
Diosque16, Omar Triana Chavez3, Christine Aznar5, Graciela Russomando13, Philippe Bu¨scher7, Azzedine
Assal4, Felipe Guhl18, Sergio Sosa Estani27, Alexandre DaSilva6, Constanc¸a Britto28, Alejandro
Luquetti29, Janis Ladzins30
1 Laboratorio de Biologı´a Molecular de la Enfermedad de Chagas (LabMECh), Instituto de Investigaciones en Ingenierı´a Gene´tica y Biologı´a Molecular (INGEBI-CONICET),
Buenos Aires, Argentina, 2 Instituto de Ca´lculo, Universidad de Buenos Aires (UBA), Buenos Aires, Argentina, 3Grupo Chagas, Universidad de Antioquia, Medellı´n,
Colombia, 4 French Blood Services, La Plaine Saint Denis, Paris, France, 5 Laboratorio Hospitalario, Universidad de Parasitologı´a, Cayene, French Guiana, 6Department of
Parasitic Diseases, Centers for Disease Control, Atlanta, Georgia, United States of America, 7 Institute of Tropical Medicine, Antwerp, Belgium, 8 Instituto Nacional de Salud,
Lima, Peru´, 9 Facultad de Medicina, Santiago de Chile, Chile, 10Universidad Nacional del Nordeste, Chaco, Argentina, 11 Instituto Nacional de Chagas, Fatala Chabe´n,
Buenos Aires, Argentina, 12Centro Universitario de Medicina Tropical, Facultad de Medicina, Universidad Mayor de San Simon, Cochabamba, Bolivia, 13 Instituto de
Investigaciones en Ciencias de la Salud, Universidad Nacional de Asuncio´n, Asuncio´n del Paraguay, Paraguay, 14 Faculdade de Farma´cia, Petro´polis, Natal, Rio Grande do
Norte, Brazil, 15 London School of Tropical Medicine and Hygiene Department of Clinical Parasitology, Hospital for Tropical Diseases, London, United Kingdom,
16 Laboratorio de Patologı´a Experimental, Universidad Nacional de Salta, Salta, Argentina, 17 Blood Bank, Hospital Sirio Libaneˆs, Sa˜o Paulo, Brazil, 18Centro de
Investigaciones en Microbiologı´a y Parasitologı´a Tropical, Universidad de los Andes, Bogota´, Colombia, 19 Instituto Pasteur, Montevideo, Uruguay, 20Centro de
Mahahonda, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Madrid, Espan˜a, 21 Seccio´n Parasitologı´a, Instituto Nacional De Salud, Santiago de Chile, Chile,
22Centro de Investigaciones Parasitolo´gicas ‘‘J.F. Torrealba,’’ Universidad de los Andes, Me´rida, Venezuela, 23 Instituto de Patologia Tropical e Sau´de Pu´blica (IPTSP),
Universidade Federal de Goia´s, Goiaˆnia, Brazil, 24Grupo de Inmunologı´a y Epidemiologı´a Molecular (GIEM), Facultad de Salud, Universidad Industrial de Santander,
Bucaramanga, Colombia, 25Departamento de Biomedicina de Enfermedades Infecciosas y Parasitarias Laboratorio de Biologı´a Celular, Centro de Investigaciones
Regionales (CIR) ‘‘Dr Hideyo Noguchi,’’ Universidad Auto´noma de Yucata´n, Yucata´n, Me´xico, 26 Instituto de Biomedicina, Universidad Cato´lica de Santiago del Estero,
Santiago del Estero, Argentina, 27Centro Nacional de Diagno´stico e Investigacio´n de Endemoepidemias (CeNDIE) ANLIS Dr. Carlos G. Malbra´n, Buenos Aires, Argentina,
28 Laborato´rio de Biologia Molecular e Doenc¸as Endeˆmicas, Instituto Oswaldo Cruz/FIOCRUZ, Rio de Janeiro, Brazil, 29 Laborato´rio de Pesquisa de Doenc¸a de Chagas,
Goia˜nia, Brazil, 30 Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization (WHO), Geneve, Switzerland
www.plosntds.org 1 January 2011 | Volume 5 | Issue 1 | e931
Abstract
Background: A century after its discovery, Chagas disease still represents a major neglected tropical threat. Accurate
diagnostics tools as well as surrogate markers of parasitological response to treatment are research priorities in the field.
The purpose of this study was to evaluate the performance of PCR methods in detection of Trypanosoma cruzi DNA by an
external quality evaluation.
Methodology/Findings: An international collaborative study was launched by expert PCR laboratories from 16 countries.
Currently used strategies were challenged against serial dilutions of purified DNA from stocks representing T. cruzi discrete
typing units (DTU) I, IV and VI (set A), human blood spiked with parasite cells (set B) and Guanidine Hidrochloride-EDTA
blood samples from 32 seropositive and 10 seronegative patients from Southern Cone countries (set C). Forty eight PCR
tests were reported for set A and 44 for sets B and C; 28 targeted minicircle DNA (kDNA), 13 satellite DNA (Sat-DNA) and the
remainder low copy number sequences. In set A, commercial master mixes and Sat-DNA Real Time PCR showed better
specificity, but kDNA-PCR was more sensitive to detect DTU I DNA. In set B, commercial DNA extraction kits presented better
specificity than solvent extraction protocols. Sat-DNA PCR tests had higher specificity, with sensitivities of 0.05–0.5 parasites/
mL whereas specific kDNA tests detected 5.1023 par/mL. Sixteen specific and coherent methods had a Good Performance in
both sets A and B (10 fg/ml of DNA from all stocks, 5 par/mL spiked blood). The median values of sensitivities, specificities
and accuracies obtained in testing the Set C samples with the 16 tests determined to be good performing by analyzing Sets
A and B samples varied considerably. Out of them, four methods depicted the best performing parameters in all three sets
of samples, detecting at least 10 fg/ml for each DNA stock, 0.5 par/mL and a sensitivity between 83.3–94.4%, specificity of
85–95%, accuracy of 86.8–89.5% and kappa index of 0.7–0.8 compared to consensus PCR reports of the 16 good performing
tests and 63–69%, 100%, 71.4–76.2% and 0.4–0.5, respectively compared to serodiagnosis. Method LbD2 used solvent
extraction followed by Sybr-Green based Real time PCR targeted to Sat-DNA; method LbD3 used solvent DNA extraction
followed by conventional PCR targeted to Sat-DNA. The third method (LbF1) used glass fiber column based DNA extraction
followed by TaqMan Real Time PCR targeted to Sat-DNA (cruzi 1/cruzi 2 and cruzi 3 TaqMan probe) and the fourth method
(LbQ) used solvent DNA extraction followed by conventional hot-start PCR targeted to kDNA (primer pairs 121/122). These
four methods were further evaluated at the coordinating laboratory in a subset of human blood samples, confirming the
performance obtained by the participating laboratories.
Conclusion/Significance: This study represents a first crucial step towards international validation of PCR procedures for
detection of T. cruzi in human blood samples.
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Introduction
A century after its discovery [1] Chagas disease still represents a
health threat to an estimated 28 million people in the Americas,
being the second highest illness burden among neglected tropical
diseases [2–3]. The infection by the protozoan Trypanosoma cruzi
can be acquired from blood-sucking triatomine bugs, blood
transfusion, transplacental transmission or by the oral contamina-
tion foodstuffs by infected triatomine faeces [2–3].
Since 1990, a series of international initiatives based on vector
control, systematic screening of blood donors in all endemic
countries, and detection and treatment of congenital transmission
have been launched for control and elimination of Chagas disease.
These strategies have led to significant reduction in the number of
infected people worldwide. According to information from 21
countries where the disease is endemic, the number of infected
persons today is estimated to be 7,694,500, most of them at the
chronic stage of disease [2–3].
Traditional parasitological procedures, such as xenodiagnosis
and haemoculture are laborious and time-consuming and show
poor sensitivities in cases of low-level parasitaemias, limiting their
usefulness in diagnosis and monitoring of drug efficacy [4–6].
Since the past decade, the application of polymerase chain
reaction (PCR) to detect T. cruzi directly in blood samples has
opened new possibilities for the diagnosis of infection and
evaluation of trypanocidal chemotherapy in different clinical and
epidemiological settings [7–22]. These PCR procedures have
revealed highly variable levels of sensitivity and specificity,
depending on a number of technical factors such as, the volume
of sample collected, the conditions of conservation of the sample,
the methods used to isolate DNA, the parasite sequences and
primers selected, the reagents used as well as the thermo-cycling
conditions. Variability in PCR sensitivity could also be in part
explained by the intermittent presence and quantity of circulating
parasites at the time of blood collection. In addition, molecular
targets from strains belonging to six different T. cruzi discrete
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typing units (DTUs, [23]) with dissimilar DNA content and gene
dosage [22,24–25] have been used for molecular diagnosis by
different laboratories. In addition, sequence polymorphisms within
amplified fragments among strains from different DTUs may
influence the efficiency of amplification [26–27]. Moreover, false
negative findings due to interference of PCR inhibitory substances
co-purified during lysis and DNA extraction of blood samples and
false positive results mostly due to carry over DNA contamination
[22,28] may arise.
In this context, the assessment of the performances of currently
available PCR tests for detection of T. cruzi infection in blood
samples and DNA control sets was launched by expert laboratories
in PCR detection of T. cruzi infection from different countries of
America and Europe. We aimed to compare the performance of
currently used PCR strategies for detection of T. cruzi DNA in sets
of blind samples, including purified DNA from reference culture
stocks from different T. cruzi discrete typing units, human blood
samples spiked with cultured parasite cells and clinical samples
from seropositive and seronegative patients from different endemic
countries, in order to select the best performing tests for validation.
Materials and Methods
The participating laboratories were selected on the basis of their
expertise in current processing of clinical samples for PCR
detection of T. cruzi DNA, facilities with pre-PCR and post-PCR
working areas and sufficient financial support to enable sustain-
ability of PCR work after conclusion of this study. Twenty six
Laboratories from different countries of America and Europe
participated in this study, one laboratory from Belgium, Bolivia,
France, French Guiana, Mexico, Paraguay, Peru, Spain, United
Kingdom, Uruguay, USA, Venezuela, two laboratories from
Chile, three from Colombia, four from Argentina and five from
Brazil.
Aiming to explore the highest extent of currently used PCR tests
for detection of T. cruzi DNA, the participating laboratories were
encouraged to carry out all available PCR strategies currently in
use according to their own protocols and using their own financial
resources (LbX1 to LbXN in Table 1, where LbX denotes
laboratory and the number denotes a given test).
The organizing laboratory (LabMECh, INGEBI, Buenos Aires)
was in charge of preparing characterised samples in three different
sets (A, B and C), as described below.
Set A. This set consisted of ten-fold serial dilutions of T. cruzi
DNA, plus three negative controls without DNA in bi-distilled
sterile water. T. cruzi DNA was purified from epimastigote cells
grown in LIT medium from stocks Silvio X10, Cl-Brener and
CAN III, which are references for the discrete typing units T. cruzi
I (DTU I), T. cruzi VI (DTU IIe) and T. cruzi IV (DTU IIa),
respectively [23,29]. The identity of the DTUs was confirmed
using a PCR algorithm targeting several nuclear genes, as detailed
in Burgos and coworkers [30]. T. cruzi DNA was extracted from
parasite cultures using current chloroform- DNA extraction
without vortexing during the procedure [31]. The concentration
and quality of DNA was measured at 260/280 nm in triplicate,
using a Nanodrop 1000 spectrophotometer (ThermoFisher
Scientific, Waltham, MA, USA). Each series of DNA samples
was conformed by concentrations ranging from 10 fg/ul to
1023 fg/ul.
Set B. This set contained seronegative human blood samples
treated with Guanidine Hidrochloride 6M-EDTA 0.2 M buffer,
pH 8.00 [32] and spiked with ten-fold dilutions of cultured CL-
Brener epimastigotes. One Guanidine Hidrochloride-EDTA
treated blood sample without parasites was included as negative
control. The samples were prepared as follows: a pool of human
blood samples testing negative for T. cruzi infection in current
serological methods and PCR was mixed with an equal volume of
Guanidine Hidrochloride-EDTA buffer. An aliquot was with-
drawn and spiked with 5 parasite cells/mL, homogenized, let
stand overnight at room temperature, boiled the following day
during 15 minutes [33], let stand at room temperature overnight
and then stored at 4uC. The remaining non-spiked blood was
treated in the same way and stored as a negative stock. One day
later, the spiked Guanidine Hidrochloride-EDTA blood was used
as starter for preparing 5 ten-fold serial dilutions, using as matrix
the negative blood stock, to obtain samples ranging from 0.5 to
5.1025 parasite equivalents/mL of blood.
Set C. This was a panel of 42 pre-characterized archived clinical
blood samples stored in Guanidine Hidrochloride-EDTA buffer,
including 10 from seronegative patients and 32 from seropositive
patients from endemic regions of Argentina, Bolivia, Brazil and
Paraguay. The seropositive panel was composed by patients at
different phases of T. cruzi infection, namely, 2 immunosuppressed
patients after heart transplantation, 23 indeterminate Chagas
disease and 7 chronic Chagas disease patients with cardiac and/or
digestive manifestations. They were selected from archived
collections from the Serodiagnostic Laboratory for Chagas
Disease, Federal University of Goias, Brazil, and from the
organizing Lab. Diagnosis was based on their serological reactivity
by at least two out of three routine serological methods (ELISA,
IHA and Latex Agglutination tests) and clinical and electrocar-
diographic findings.
Samples from patients were obtained with written informed
consent and approval of the Ethics Committee of the Rivadavia
Hospital, Government of Buenos Aires city, Argentina and the
Serodiagnostic Laboratory for Chagas Disease, Federal University
of Goias, Goiania, Brazil. Furthermore, all samples were tested by
two PCR tests performed on duplicate at the organizing
laboratory, namely a hot-start PCR targeting kDNA according
to Burgos et al [30], a Real time PCR targeting satellite DNA
sequences and a Real time PCR targeting an internal amplifica-
Author Summary
A century after its discovery, Chagas disease, caused by the
parasite Trypanosoma cruzi, still represents a major
neglected tropical threat. Accurate diagnostics tools as
well as surrogate markers of parasitological response to
treatment are research priorities in the field. The polymer-
ase chain reaction (PCR) has been proposed as a sensitive
laboratory tool for detection of T. cruzi infection and
monitoring of parasitological treatment outcome. Howev-
er, high variation in accuracy and lack of international
quality controls has precluded reliable applications in the
clinical practice and comparisons of data among cohorts
and geographical regions. In an effort towards harmoni-
zation of PCR strategies, 26 expert laboratories from 16
countries evaluated their current PCR procedures against
sets of control samples, composed by serial dilutions of
T.cruzi DNA from culture stocks belonging to different
lineages, human blood spiked with parasite cells and
blood samples from Chagas disease patients. A high
variability in sensitivities and specificities was found
among the 48 reported PCR tests. Out of them, four tests
with best performance were selected and further evaluat-
ed. This study represents a crucial first step towards device
of a standardized operative procedure for T. cruzi PCR.
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Table 1. PCR tests reported by the participating Laboratories.
Lb/Test Extraction Method Target Primer Names PCR Master Mix Cycles
LbA Solvent extraction kDNA 121-122 Conventional In-House 35
LbB Solvent extraction kDNA S35 - S36 Conventional In-House 30
LbC/1 Solvent extraction kDNA S35 - S36 Conventional In-House 32
LbC/2 Solvent extraction Sat-DNA tcz1 - tcz2 Conventional In-House 40
LbC/3 Solvent extraction 24s D71-D71 Conventional In-House 40
LbC/4 Solvent extraction CO II-DNA Tcmit 31-40 Conventional In-House 48
Lb/C5 Solvent extraction CO II-DNA Nested Tcmit 10-21 Conventional In-House 48
Lb/C6 Solvent extraction SL-DNA Tcc- Tc1-Tc2 Conventional In-House 30
Lb/D1 Solvent extraction kDNA 121-122 Conventional In-House 36
Lb/D2 Solvent extraction Sat-DNA TczF-TczR Real Time Qiuantitect (Kt) 50
Lb/D3 Solvent extraction Sat-DNA TczF-TczR Conventional In-House 41
LbE Chelex Resine kDNA 121-122 Conventional In-House 35
LbF/1 Roche Silica gel col (Kt) Sat-DNA cruzi1-2 Real Time Roche (Kt) 45
LbF/2 Roche Silica gel col (Kt) kDNA 32f-148r Real Time Roche (Kt) 45
LbG/1 Qiagen DNeasy Tissue kit (Kt) kDNA FAM – IPC 32f-148r Real Time Apllied Biosystem (Kt) 55
LbG/2 Qiagen DNeasy Tissue kit (Kt) kDNA FAM 32f-148r Real Time Apllied Biosystem (Kt) 55
LbG/3 Qiagen DNeasy Tissue kit (Kt) kDNA VIC 32f-148r Real Time Apllied Biosystem (Kt) 55
LbG/4 Qiagen DNeasy Tissue kit (Kt) Sat-DNA cruzi1-2 Real Time Apllied Biosystem (Kt) 45
LbH/1 Favorgen Glass fibers col (Kt) kDNA 121-122 Conventional GoTaq (Kt) 33
LbH/2 Favorgen Glass fibers col (Kt) kDNA 121-122 Conventional In-House 33
LbI/1 Favorgen Glass fibers col (Kt) kDNA 121-122 Conventional In-House 40
LbI/2 Favorgen Glass fibers col (Kt) kDNA S35 - S36 Conventional In-House 40
LbJ Solvent extraction Sat-DNA Tcz1-Tcz2 Conventional In-House 40
LbK/1 Silica gel col (Kt) Sat-DNA cruzi1-2 Real Time In-House 40
LbK/2 Silica gel col (Kt) kDNA 121-122 Conventional In-House 40
LbL/1 Blood mini Kit (Kt) Sat-DNA cruzi1-2 Conventional In-House 40
LbL/2 Blood mini Kit (Kt) Sat-DNA Satellite DNA based kit Conventional OligoC-T Coris (Kt) 40
LbM Silica gel col (Kt) kDNA TC1-TC2 Conventional In-House 40
LbN/1 Solvent extraction kDNA 121-122 Conventional In-House 40
LbN/2 Solvent extraction Sat-DNA Tcz1-Tcz2 Conventional In-House 35
LbO Solvent extraction kDNA 121-122 Conventional In-House 40
LbP/1 Solvent extraction kDNA 121-122 Conventional In-House 35
LbP/2 CTAB (IH) kDNA 121-122 Conventional In-House 35
LbQ Solvent extraction kDNA 121-122 Conventional In-House 37
LbR Roche Silica gel col (Kt) kDNA 121-122 Conventional In-House 40
LbS/1 Qiagen Silica gel col (Kt) 18s Tc18s F3-R4 Conventional AmpliTaq Gold (Kt) 40
LbS/2 Qiagen Silica gel col (Kt) Sat-DNA cruzi1-2 Real Time Platinum qPCR (Kt) 40
LbS/3 Qiagen Silica gel col (Kt) 18s Tc18s F1042- R1144 Real Time Platinum qPCR (Kt) 40
LbS/4 Qiagen Silica gel col (Kt) kDNA 121-122 Conventional AmpliTaq Gold (Kt) 40
LbT ATGEN kit (Kt) kDNA 121-122 Real Time Invitrogen (Kt) 40
LbU/1 Solvent extraction kDNA 121-122 Conventional In-House 40
LbU/2 Solvent extraction 24s D71-D72 Conventional In-House 32
LbV/1 Silica gel col (Kt) kDNA 121-122 Conventional In-House 40
LbV/2 Silica gel col (Kt) Sat-DNA Tcz1-Tcz2 Conventional In-House 30
LbW Solvent extraction kDNA 121-122 Conventional In-House 40
LbX Solvent extraction kDNA 121-122 Conventional In-House 35
LbY Solvent extraction kDNA 121-122 Conventional In-House 35
LbZ Silica gel col (Kt) Sat-DNA cruzi1-2 Real Time TaqMan Univ (Kt) 45
LbX/1-6, Laboratory and test identification, kDNA, minicircle DNA; Sat-DNA, satellite DNA; 24s, 24sa rDNA; 18s, 18s rDNA; SL, Spliced Leader; kDNA FAM, kDNA TaqMan
probe labeled with FAM; kDNA VIC, kDNA TaqMan probe labeled with VIC; IPC, TaqMan Exogenous Internal Positive Control (Applied Biosystems).
doi:10.1371/journal.pntd.0000931.t001
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tion control, according to Duffy and coworkers [22], allowing
confirmation of PCR negativity among seronegative samples and
PCR positivity among a subgroup of the 32 seropositive samples
(data not shown).
Each sample from set A, B and C was aliquoted and distributed
into 1 ml Screw Top bar-coded tubes (Matrix Trackmates,
UNITEK, USA) to each package. The packages were sent
refrigerated to the participating laboratories (World Courier, Arg).
Each laboratory received 50 mls of Set A and 500 mls of samples
belonging to sets B and C.
Best Performing PCR Methods
DNA extraction. Methods LbD2, LbD3 and LbQ: Solvent
DNA extraction was carried out from 100 ml of Guanidine
Hidrochloride-EDTA blood aliquots. Briefly, 100 ml aliquots were
taken and well mixed with 100 m l of phenol-chloroform-isoamylic
alcohol (25:24:1) (phenol Tris–EDTA pH 8, USB Corporation,
USA). After centrifugation for 3 min at 13000 rpm 150 ml of
distilled water were added. The solution was mixed and
centrifuged for 3 min at 13000 rpm. The aqueous phase was
transferred to a clean tube, and a final extraction with 200 m l of
chloroform was performed. After centrifugation for 3 min at
13000 rpm the aqueous phase was transferred to a clean tube and
mixed with 40 mg of rabbit liver glycogen (Sigma, USA). The
DNA was precipitated with 200 ml of isopropyl alcohol during 30
minutes at 220uC. Then the solution was centrifuged at
13000 rpm for 15 min. The pellet was washed with 500 ml of
70% ethanol and centrifuged again 15 min at 13000 rpm. After
discard the ethanol the pellet was allowed to dry during 10 min at
37uC. Finally the pellet was suspended in 50 ml 10 mM Tris-HCl,
pH 8.5. DNA solution was stored at 220uC. Method LbF1: DNA
isolation used a commercial kit (High Pure PCR Template
preparation kit, Roche Applied Science) according to the
manufacturer’s protocol. DNA solution was stored at 220uC.
DNA amplification. Method LbD3 was carried out in a MJR
PTC-100 thermocycler (MJ Research, Watertown, MA, USA).
Master mix was composed by 1X Taq platinum amplification
buffer, 250 mM deoxynucleotide triphosphate solution (dNTPs),
3 mM MgCl2 solution, 1,5 U Taq Platinum (Invitrogen, Brazil),
0.5 mM sat-DNA specific primers TCZ-F (GCTCTTGCCCA-
CAMGGGTGC) and TCZ-R (CCAAGCAGCGGATAGTTC-
AGG), 5 ml of template DNA and a quantity of water sufficient to
give a final volume of 50 ml. Cycling parameters were one step of
3 min at 94uC; 40 cycles of 45 sec at 94uC, 1 min at 68uC and
1 min at 72uC and one final extension step of 10 min at 72uC,
182 bp Sat-DNA PCR products were analysed in 3% agarose gels
(Invitrogen, Life Technologies, USA) stained with ethidium
bromide.
Method LbQ was carried out in a MJR PTC-100 thermocycler
(MJ Research, Watertown, MA, USA). Master mix was composed
by 1X Taq platinum amplification buffer, 200 m M dNTPs, 3 mM
MgCl2 solution, 1,5 U Taq Platinum (Invitrogen, Brazil), 10 mM
kDNA specific primers 121 (AAATAATGTACGGGKGA-
GATGCATGA) and 122 (GGTTCGATTGGGGTTGGTG-
TAATATA), 7.5 ml of template DNA and a quantity of water
sufficient to give a final volume of 50 ml. Cycling parameters were
one step of 3 min denaturation at 94uC; 2 cycles of 1 min at
97.5uC, 2 min at 64uC; 33 cycles of 1 min at 94uC, 1 min at 62uC
and one final extension step of 10 min at 72uC, 330 bp kDNA
PCR products were analysed in 2% agarose gels stained with
ethidium bromide.
Method LbD2 was conducted using a Rotor Gene 3000
(Corbett Research, Sydney, Australia) Real Time thermocycler.
Each PCR reaction contained 1X Qiagen QuantiTect Sybr-Green
PCR Master Mix (Qiagen), 0.5 mM SatDNA specific primers
TCZ-F (GCTCTTGCCCACAMGGGTGC) and TCZ-R (CCA-
AGCAGCGGATAGTTCAGG), 2 ml of template DNA and
PCR-grade H2O (Qiagen) to a final volume of 20 ml. The
amplification was conducted under the following cycling condi-
tions after 15 min of denaturation at 95uC, PCR amplification was
carried out for 50 cycles (95uC for 10 s, 55uC for 15 s and 72uC
for 10 s). Fluorescence data collection was performed at 72uC at
the end of each cycle. After quantification, a melt curve was made
with 74–85uC raising by 0.5uC each step and waiting for 4 seconds
afterwards acquiring on Green channel. Melting temperture (Tm)
of the amplicon was 81uC. Finally, data were analyzed with Rotor-
Gene 6000 Series Software 1.7 (Corbett Research).
Method LbF1 was conducted using a Rotor Gene 3000 (Corbett
Research, Sydney, Australia) Real Time thermocycler. Each PCR
reaction contained 1X PCR FastStart Universal Probe Master
Master Mix (Roche), 0.75 mM SatDNA specific primers cruzi 1
(ASTCGGCTGATCGTTTTCGA) and cruzi 2 (AATTCCTC-
CAAGCAGCGGATA), 0.25 mM SatDNA specific probe cruzi 3
(CACACACTGGACACCAA), 2 ml of template DNA and PCR-
grade H2O to a final volume of 20 ml. The amplification was
conducted under the following cycling conditions, after 15 min of
denaturation at 95uC, 45 cycles at 95uC for 10 s, 54uC for 60 s.
Fluorescence data collection was performed at 54uC at the end of
each cycle. Finally, data were analyzed with Rotor-Gene 6000
Series Software 1.7 (Corbett Research).
The possibility of contamination of the PCR reagents and of the
solutions used to prepare DNA was carefully examined through
the use of appropriate controls. Also two dilutions from DNA
purified from Cl- Brener strain were analyzed in each round as
strong positive and detection limit control, respectively.
Data Analysis
An access database form was distributed to the participants to
standardize reporting of results. Those laboratories performing
more than one PCR test per sample sent a separate report for each
test. The results were analyzed by using SAS Software and
Microsoft Excel. Due to the exploratory nature of the study, a
descriptive analysis of results is provided.
For set A, the following parameters were evaluated: 1) specificity
(Sp): the proportion of negative PCR results in the three negative
samples, 2) coherence: (Co) the ability of reporting positive PCR
findings in a consecutive way, from the highest to the lowest
detected DNA concentration for each series of DNA dilutions of
parasite stocks and 3) the detection limits (DL) for each stock. A
test was defined as Good Performing Method (GPM) if it was
100% specific and coherent and capable of detecting 10 fg/ul or
less DNA for all parasite DTU stocks.
For set B the same parameters were evaluated: Sp, Co and DL.
A test was defined as GPM if it was 100% specific and coherent
and capable of detecting 5 parasite equivalents/mL of Guanidine
Hidrochloride-EDTA treated blood or less.
For each sample of set C, a consensus PCR result was obtained
on the basis of the reports by GPM tests in sets A and B, as done in
other PCR interlaboratory studies [34]. A sample was considered
PCR positive by consensus if more than 50% of the GPM gave
positive results and PCR negative if more than 50% of GPM tests
gave negative results. Those samples for which 50% of the GPM
methods gave positive reports and 50% gave negative ones were
considered indeterminate.
The sensitivity, specificity, accuracy and kappa index of the
different PCR tests were calculated by using 1) the above
mentioned consensus PCR results and 2) the serological diagnosis
as the reference methods.
International PCR Study for T.cruzi Detection
www.plosntds.org 5 January 2011 | Volume 5 | Issue 1 | e931
Inter-observer kappa coefficients were calculated using Graph-
Pad Software on-line statistical calculators (http://www.graphpad.
com/quickcalcs/kappa1. cfm). Kappa values,0.01 indicate no
concordance, those between 0.1 and 0.4 indicate weak concor-
dance, those between 0.41 and 0.60 indicate clear concordance,
those between 0.61 and 0.80 indicate strong concordance, and
those between 0.81 and 1.00 indicate nearly complete concor-
dance. Accuracy was calculated as reported [35].
Results
Twenty six laboratories reported PCR results, using one to six
different PCR tests (Table 1). The main sources of variability
among laboratories and tests included DNA purification proce-
dures using commercial kits (Kt) or in-house methods (IH), T. cruzi
target and primer sequences, cycling instrumentation by conven-
tional (C) or Real Time (RT) thermocyclers, cycling conditions,
master mix compositions and trade marks of PCR kits (Kt) or
reagents for IH master mixes.
A total of 48 PCR tests were reported for set A samples and 44
of them for sets B and C. Twenty eight tests targeted minicircle
DNA, 24 of them amplified the 330 bp variable region and 4
amplified a 118 bp fragment from the constant region (Lb F2 and
Lb G1 to G3, Table 1). Thirteen tests targeted the satellite DNA
sequence (Sat-DNA), two targeted the 18s ribosomal RNA genes
(18s rDNA), two amplified a fragment from the 24sa ribosomal
RNA genes (24sa rDNA), one targeted the intergenic region of
spliced-leader genes (SL-DNA) and two the mitochondrial gene for
the subunit II of cytochrome oxidase (CO II-DNA) (Table 1).
Analysis of Set A
Table 2 shows the data obtained by the 48 PCR tests on DNA
dilutions from the 3 parasite stocks representing DTUs I, IV and
VI. The seven PCR tests targeting sequences other than Sat-DNA
or kDNA failed to detect the most concentrated DNA sample
(10 fg/ul) of one, two or all three parasite stocks (Tests C3, C4,
C6, S1 and S3; Detection Limit = ND), or reported false positive
findings in the negative controls without DNA (Tests C5 and U2)
and thus were not included in the following analysis.
Out of the 41 tests based on kDNA (28 tests) or Sat-DNA
sequences (13 tests), 25 (51.2%) provided specific and coherent
results for all three parasite stocks (Sp = Y, Co = Y, Table 2).
Fourteen of them targeted kDNA, representing 50% of the
reported kDNA-PCR tests and 11 targeted Sat-DNA, representing
84.6% of Sat-DNA PCR tests. These data indicated that PCR tests
based on Sat-DNA sequences were more specific than those based
on kDNA. Figures 1A and 1B show the distribution of the
detection limits (DL) of the above mentioned 11 Sat-DNA PCR
and 14 kDNA PCR tests, respectively, for each T. cruzi stock.
Analysis of T. cruzi I DNA series: Nine out of 11 Sat-DNA- and
all 14 kDNA-PCR tests were capable of detecting at least the most
concentrated T. cruzi I DNA sample (Figure 1 A and B, grey bars)
and 2 Sat-DNA and 8 kDNA-PCR tests could detect 0.1 fg/ml of
T. cruzi I DNA. The lowest detection limit for T. cruzi I DNA was
0.01 fg/ul obtained by laboratory W using conventional kDNA-
PCR (Table 2 and Figure 1B). Thus, kDNA- PCR tests were more
sensitive than Sat-DNA PCR tests to detect T. cruzi I DNA.
Analysis of T. cruzi IV DNA series: 8 out of 11 Sat-DNA- and all
14 kDNA-PCR tests were capable of detecting the most
concentrated T. cruzi IV DNA sample (Figure 1 A and B, black
bars). The lowest detection limit (1 fg/ml) was reached by three
Sat-DNA- and six kDNA-PCR tests, suggesting similar analytical
sensitivities of methods based on both molecular targets to detect
T. cruzi IV DNA.
Analysis of T. cruzi VI DNA series: All 11 Sat-DNA- and 13 out
of 14 kDNA-PCR tests were capable of detecting the most
concentrated T. cruzi VI DNA sample (Figure 1 A and B, white
bars). The only test that did not detect Cl-Brener DNA amplified
the constant kDNA region (G1, kDNAc, Table 2). The lowest
detection limit (0.01 fg/ml) was obtained by 2 Sat-DNA PCR tests
(Z and F1, Table 2) followed by 0.1 fg/ml obtained by 2
conventional kDNA-PCR tests (R and W, Table 2).
Overall, the reported PCR tests were less sensitive for detecting
DNA from the T. cruzi IV reference stock. Twenty PCR tests
showing specific and coherent results and detecting at least the
most concentrated DNA samples from each of the parasite stocks
were considered Good Performing Methods for Set A (bold fonts,
Table 2). They comprised 53.8% of 13 Sat-DNA-PCR and
46.42% of 28 kDNA-PCR tests. Ten GPM tests used in-house (IH)
PCR mixtures and 10 used commercial master mixes (Kt),
representing 35.7% of the 28 IH and 76.9% of the 13 Kt PCR
reagent mixes. In addition, 12 GPM used conventional amplifi-
cation and eight used real time PCR (C and RT in Table 2),
representing 38.7% of 31 C and 72.7% of 11 RT tests. These data
showed that commercial master mixes and real time PCR offered
better PCR performance in purified DNA samples.
Analysis of Set B
Out of the 44 PCR tests reported for spiked Guanidine
Hidrochloride-EDTA blood samples, the three tests targeting
sequences other than Sat-DNA or kDNA were not further
analyzed, because they failed to detect the most concentrated
sample (S1 and S3 tests) or showed false positive findings in the
non-spiked control (U2 test) (Set B, Table 2).
Twenty five out of 41 PCR tests based on kDNA and Sat-DNA
sequences showed specific, coherent results and detection limits of
at least 5 par/ml (GPM, bold fonts, Table 2, Set B). They included
14 kDNA and 11 Sat-DNA PCR tests, representing 50% of 28
kDNA and 84.6% of 13 Sat-DNA based tests. Ten GPM used in-
house extraction methods and 15 used DNA extraction kits,
representing 41.6% of 24 IH and 62.5% of 24 Kt tests. Thus,
methods using commercial DNA extraction and Sat-DNA as
amplification target resulted in better performance. Procedures
based on kDNA presented more variation in sensitivity than Sat-
DNA tests (Figure 1C, white bars). The smallest detected
concentration was 561023 par/ml, recorded by three laboratories
using conventional kDNA-PCR after DNA extractions with
Chelex resine, a blood extraction kit or solvent extraction with
Phenol (LbE, LbL1 and LbW, respectively, Table 1). Tests based
on Sat-DNA presented sensitivities between 0.05 and 0.5 par/ml
(10/11 tests, Figure 1C, black bars) with the only exception of one
test based on solvent DNA extraction and IH conventional Sat-
DNA PCR (C2, Table 1) that reached a detection limit of
561025 par/mL (Table 2, and Figure 1C).
Analysis of Set C
Out of the 44 PCR tests performed on clinical samples of Set C, a
18s-rDNA PCR (S3) and a SL-DNA PCR (C6) tests did not detect
any positive sample and the 24s a rDNA-PCR test (U2) had only
40% of specificity. Consequently, they were not included for
subsequent analysis. The levels of agreement among the 41
remaining PCR tests on the reports for each clinical sample are
presented in Table 3. For each sample, 3 series of consensus PCR
results were calculated: 1) consensus based on the 28 kDNA-PCR
tests, 2) consensus based on the 13 Sat-DNA PCR tests and 3)
consensus based on the 16 tests defined as GPM in both sets A and B
samples. The sensitivity of consensus kDNA-PCR was 65.62% (21
PCR positive/32 seropositive samples), that of consensus Sat-DNA
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Table 2. Performances of PCR tests in Sets A and B.
Set A Set B GPM
T. cruzi I T. cruzi IV T. cruzi VI T. cruzi VI
Lb/Test Sp Co DL Co DL Co DL Sp Co DL par/ml
LbA Y Y 0.1 N 0.01 N 0.01 Y N 0.005 N
LbB Y N 0.001 N 0.001 Y 0.1 Y N 0.005 N
LbC/1 N N 0.001 N 0.001 Y 0.1 N Y ND N
LbC/2 Y Y ND N 1 Y 10 Y Y 0.00005 N
LbC/3 Y Y ND Y ND Y ND NA NA NA N
LbC/4 Y Y ND Y ND Y ND NA NA NA N
Lb/C5 N Y 1 N 0.1 N 0.001 NA NA NA N
Lb/C6 Y Y ND Y ND Y ND NA NA NA N
Lb/D1 Y Y 1 Y 10 Y 1 N N 0.005 N
Lb/D2 Y Y 1 Y 10 Y 1 Y Y 0.05 Y
Lb/D3 Y Y 1 Y 10 Y 1 Y Y 0.05 Y
LbE Y Y 1 Y 10 Y 10 Y Y 0.005 Y
LbF/1 Y Y 0.1 Y 1 Y 0.01 Y Y 0.05 Y
LbF/2 Y Y 1 N 0.01 Y 1 Y Y 0.5 N
LbG/1 Y Y 0.1 Y 1 Y ND Y Y 0.05 N
LbG/2 Y Y 0.1 Y 1 Y 1 Y Y 0.05 Y
LbG/3 Y Y 0.1 Y 1 Y 1 Y Y 0.05 Y
LbG/4 Y Y 1 Y 1 Y 1 Y Y 0.5 Y
LbH/1 Y Y 1 Y 10 N 0.001 Y N 0.05 N
LbH/2 Y Y 1 N 0.1 Y 10 Y N 0.05 N
LbI/1 Y Y 1 N 0.001 Y 10 Y Y 0.005 N
LbI/2 Y Y 1 Y 10 Y 10 Y Y 0.05 Y
LbJ Y Y 0.01 N 0.001 N 0.001 Y N 0.5 N
LbK/1 Y Y 10 Y 10 Y 10 Y Y 0.5 Y
LbK/2 Y Y 1 Y 10 Y 10 Y Y 5 N
LbL/1 Y Y ND Y 10 Y 1 Y Y 0.5 N
LbL/2 Y Y ND Y ND Y 1 Y Y 0.5 N
LbM N Y 0.001 Y 0.001 N 0.001 Y Y ND N
LbN/1 Y Y 0.1 Y ND N 0.1 Y N 0.005 N
LbN/2 Y Y 1 Y ND Y 10 Y Y 0.5 N
LbO Y Y 10 N 1 Y ND Y Y 0.05 N
LbP/1 Y Y 0.1 Y 10 Y 1 Y Y 5 N
LbP/2 Y Y 0.1 Y 10 Y 1 Y Y 0.5 N
LbQ Y Y 1 Y 10 Y 1 Y Y 0.5 N
LbR Y Y 0.1 Y 1 Y 0.1 Y N 0.00005 N
LbS/1 Y Y 1 Y ND Y ND Y Y ND N
LbS/2 Y Y 1 Y 10 Y 1 Y Y 0.5 N
LbS/3 Y Y 10 Y 10 Y ND Y Y ND N
LbS/4 Y Y 1 Y 1 Y 10 N N 0.00005 N
LbT N N 0.001 Y 1 N 0.01 N N 0.05 N
LbU/1 N Y 0.001 Y 0.001 Y 0.001 Y N 0.005 N
LbU/2 N Y 0.001 Y 0.001 Y 0.001 N N 0.005 N
LbV/1 Y Y 0.1 Y 10 Y 10 Y Y 0.05 N
LbV/2 Y Y 0.1 Y ND Y 10 Y Y 0.05 N
LbW Y Y 0.01 Y 1 Y 0.1 Y Y 0.005 N
LbX N N 0.01 N 0.001 N 0.1 Y N 0.0005 N
LbY N Y 1 Y 1 Y 0.1 Y Y ND N
LbZ Y Y 1 Y 1 Y 0.01 N N 0.0005 N
Table 2. Cont.
LbX/1-6, Laboratory and test identification; Bold Type, Good Performing
Methods in sets A or B; GPM, Good Performing Methods in sets A and B; Sp,
100% of specificity in all controls without T. cruzi DNA; Co, Coherence in PCR
positive reports; DL, Detection limit in fg DNA/ul; Y, Affirmative; N, Negative; NA,
Not available; ND, Not detectable.
doi:10.1371/journal.pntd.0000931.t002
Figure 1. Analytical Sensitivity of specific and coherent PCR
tests in sets A and B. Distribution of detection limits (DL) of specific
and coherent PCR tests targeted to Sat-DNA (A) and kDNA sequences
(B) for detecting serial dilutions of purified DNA from 3 parasite stocks
(Set A) representative of T. cruzi DTU I (Silvio610), DTU IV (Can III cl1)
and DTU VI (Cl Brener). C. Distribution of detection limits (DL) of specific
and coherent PCR tests targeted to Sat-DNA (black bars) and kDNA
sequences (white bars) carried out from human blood spiked with serial
dilutions of parasite cells (Set B).
doi:10.1371/journal.pntd.0000931.g001
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was 62.5% (20 PCR positive/32 seropositive samples) and that of
consensus GPM was 56.25% (B (18 PCR positive/32 seropositive
samples) being 4 samples indeterminate (13, 18, 20, 21, Table 3)
because the levels of agreement among GPM tests was 50%.
The individual performance of the 41 PCR tests was evaluated
in comparison with the consensus PCR results reached by the 16
GPM in sets A and B (18 PCR positive, 20 PCR negative samples)
and in comparison with serologic diagnosis (10 seronegative, 32
seropositive samples) (Table 4). There was a high variability
among the performances of the different methods (Table 4). The
median values of sensitivity, specificity and accuracy of the 41 tests
were 72, 77.5 and 68.4%, respectively in comparison to consensus
GPM PCR reports, and 59.4, 70 and 59.5%, respectively in
comparison to serological diagnosis (Table 4).
Best Performing Methods
Four GPM showed the best operational parameters in set C
(Table 4). Tests LbD2 and LbD3 used solvent DNA extraction
followed by conventional hot-start and Real time PCR targeted to
Sat-DNA, respectively (primer pairs TCZ-F/TCZ-R). Test LbF1
used a commercial kit for DNA extraction based on glass fiber
columns and Real Time PCR targeted to Sat-DNA (primer pairs
cruzi 1/cruzi 2 and TaqMan probe cruzi 3) and test LbQ used
solvent DNA extraction and conventional hot-start PCR for
kDNA (primer pairs 121/122).
The performance of these four tests was further evaluated at the
coordinating laboratory on a subset of samples from seropositive
and seronegative patients, analysed in four independent experi-
ments (Table 5). Examples of the outputs of each method are shown
in Figure 2. The degree of concordance among the reported results
by the BPM was between 87.5% and 90.62%. This intralaboratory
evaluation showed that the selected methods depicted similar
operational parameters than when performed by the corresponding
laboratories in the international study (Tables 4 and 6).
Discussion
PCR technology has been widely used for the diagnosis and
monitoring of disease progression and therapy outcome in many
infectious diseases [28]. Since 1989, PCR strategies have been
developed aiming to analyse clinical samples infected with T. cruzi
[7,36]. However, each laboratory has applied its own protocols
and quality controls, making comparison of PCR based findings
among different research groups and geographical regions not
reliable. This international collaborative study is a crucial first step
aiming at the evaluation of currently used PCR procedures for
detection of T. cruzi infection, towards the assessment of a standard
operative procedure.
Out of the 48 PCR tests reported by 26 laboratories, those
targeting ribosomal, miniexon or CO II subunit gene sequences
were not sensitive enough when challenged against 10 fg/ml or less
of purified DNA from the 3 tested parasite stocks, to merit further
consideration. Thus, these methods appeared not suitable for
sensitive molecular diagnosis of Chagas disease in clinical settings.
However, these parasitic targets are been widely used for
genotyping parasite discrete typing units [29–30,37–41], mito-
chondrial gene haplotypes [42] or miniexon based T. cruzi I
genotypes [43–44]. In this regard, multicentric evaluation and
standardization of PCR based genotyping methods for identifica-
tion of T. cruzi DTUs is needed.
PCR Performance in Set A Samples
In set A, GPM included kDNA and sat-DNA PCR tests in
similar proportions. However, Sat-DNA PCR tests were less
sensitive than kDNA-PCR tests to detect T. cruzi I DNA. This is
most likely due to the fact that T. cruzi DTU I harbors
approximately four to ten-fold less number of satellite repeats
than DTUs II, V and VI, which has been demonstrated by
different molecular approaches [22,45].
Regarding T. cruzi IV that also harbors a lower dosage for satellite
sequences [22], similar analytical sensitivities of kDNA and Sat-
DNA PCR tests were observed, being lower than that obtained for
the other two tested DTU representative stocks. The genome size
and relative DNA contents of Can III cl1 (116.44 Mb, 95% CI
110.4–122.63 and 1.090, respectively) and CL Brener (108.55 Mb,
95% CI 101.41–115.89 and 1.017) are similar [25], although Can
III cl1 harbors about 5 fold less satellite repeats than CL-Brener
[22]. The relative contribution of the nucleus and kinetoplast has
not been measured but normally, kDNA represents 20–25% of the
total DNA content [46]. There are no available data regarding the
number of minicircles in the kinetoplast of Can III cl1, so it could be
speculated that the lower analytical sensitivity of most PCR tests to
detect DNA from this clone respect to the other ones, could be due
to a lower minicircle copy dosage.
PCR Performance in Set B Samples
Set B allowed evaluation of the influence of DNA extraction
procedures in the PCR performance. A 72.2% of DNA extraction
methods based on commercial kits led to GPM in set B, whereas
57.8% of phenol-chlorophorm extracted DNA led to GPM
reports. These findings indicated that Guanidine Hidrochloride-
EDTA blood was suitable for DNA extraction using kits based on
lysis buffers containing Guanidine salts.
Out of the 25 GPM in set B, 14 had a sensitivity of 0.05 par/ml,
which should be adequate for diagnosis of infection in chronic
patients [20]. Indeed, the necessary detection limit in chronic
Chagas disease has been stated as one parasite cell in 10 mL of
blood [20].
PCR Performance in Set C Samples
Analysis of PCR performance in set C clinical samples showed
that the four best performing tests presented strong concordance
with respect to consensus PCR results obtained by the 16 tests
defined as GPM in sets A plus B (kappa index between 0.7 and
0.8). Out of them, three tests targeted sat-DNA sequences and only
one targeted kDNA. These data are in agreement with previous
works showing that PCRs targeting Sat-DNA performed better
than PCRs targeting kDNA sequences [47–49], although kDNA
based PCR has been more widely used [20].
Moreover, two of the sat-DNA best performing tests used Real
Time PCR, one with a Sybr Green fluorescent dye (LbD2) and the
other one with a TaqMan probe (LbF1). It must be pointed out that
LbD2 and LbD3 tests were performed by the same laboratory. Out
of the 16 GPM performed by 11 different laboratories, 3
laboratories performed two methods (LbD, LbK and LbP) and
one lab developed 3 tests (LbG). These data point to laboratory
dependence concerning PCR performance, which may be due to
multiple factors including technical expertise, correct use of quality
controls, instrumentation and reagents. For example, tests LbF1,
LbS2 (GPM) and LbZ (not GPM) were all based on sat-DNA Real
Time PCR using the same primer pair (cruzi 1 – cruzi 2), differing in
the trade marks of the DNA extraction and Master Mix kits. Some
tests shown as GPM in sets A+B had very low sensitivities in set C
(LbK2, LbP2, LbV1, Table 4), suggesting that quality controls
might have failed to distinguish false negative clinical samples.
A major drawback of most PCR tests is that they do not contain
an internal amplification control (IAC). An IAC is a non target
DNA sequence present in the same sample reaction tube, which is
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Table 3. Concordance of PCR results reported for each clinical case of Set C.
CLINICAL CASES kDNA PCR n = 28 Sat-DNA PCR n = 13 GPM n = 16
ID G Ag Status Region EN pos/tot % Cons pos/tot % Cons pos/tot % Cons
1 F NA cChHD-HTx Arg- Uk1 Uk 26 92,9 P O S 12 92,3 P O S 15 93,8 P O S
2 M NA cChHD-HTx Arg-Chaco1 Yes 26 92,9 P O S 10 76,9 P O S 15 93,8 P O S
3 F 54 Mega III cChH Br- MG Yes 20 71,4 P O S 12 92,3 P O S 12 75,0 P O S
4 F 42 Pregnant Arg- Salta2 Yes 18 64,3 P O S 12 92,3 P O S 14 87,5 P O S
5 F 25 Pregnant Bo-Uk Yes 18 64,3 P O S 11 84,6 P O S 12 75,0 P O S
6 M 20 Blood donor Br-BA Yes 19 67,9 P O S 10 76,9 P O S 10 62,5 P O S
7 F 41 cChHD Br-BA Yes 18 64,3 P O S 9 69,2 P O S 11 68,8 P O S
8 F 31 Pregnant Bo-Uk Yes 16 57,1 P O S 10 76,9 P O S 11 68,8 P O S
9 F NA Pregnant Par-Uk2 Yes 15 53,6 P O S 11 84,6 P O S 12 75,0 P O S
10 F 22 Ex-pregnant Br-BA Yes 17 60,7 P O S 10 76,9 P O S 12 75,0 P O S
11 F 41 Chronic CD Br-BA Yes 16 57,1 P O S 9 69,2 P O S 11 68,8 P O S
12 F 24 Ex-pregnant Br-Go Yes 15 53,6 P O S 9 69,2 P O S 10 62,5 P O S
13 F 32 Pregnant Arg-Co Yes 16 57,1 P O S 8 61,5 P O S 8 50,0 I N D
14 F 35 Ex-pregnant Br-Ceara Yes 17 60,7 P O S 9 69,2 P O S 12 75,0 P O S
15 F 47 cChHD Br-Go Yes 17 60,7 P O S 8 61,5 P O S 9 56,3 P O S
16 F NA Pregnant Par-Uk Yes 14 50,0 P O S 8 61,5 P O S 9 56,3 P O S
17 M 55 CD Br-MG Yes 15 53,6 P O S 7 53,8 P O S 10 62,5 P O S
18 M 33 cChHD Br-BA Yes 15 53,6 P O S 7 53,8 P O S 8 50,0 I N D
19 F 66 Mega II + CBBB Br-BA Yes 15 53,6 P O S 5 38,5 N E G 9 56,3 P O S
20 F 18 Ex-pregnant Br-Go Yes 16 57,1 P O S 4 30,8 N E G 8 50,0 I N D
21 F 18 Pregnant Arg-Sg Yes 15 53,6 P O S 6 46,2 N E G 8 50,0 I N D
22 F 43 Indeterminate CD Br-BA Yes 13 46,4 N E G 7 53,8 P O S 6 37,5 N E G
23 F 57 Blood donor Br-Piaui Yes 11 39,3 N E G 8 61,5 P O S 9 56,3 P O S
24 F 46 Blood donor Br-BA Yes 7 25,0 N E G 6 46,2 N E G 6 37,5 N E G
25 F 25 Pregnant Par-Uk2 Yes 10 35,7 N E G 5 38,5 N E G 5 31,3 N E G
26 F 32 Pregnant Par-Uk2 Yes 11 39,3 N E G 5 38,5 N E G 6 37,5 N E G
27 F 36 Pregnant Arg-Chaco Yes 11 39,3 N E G 5 38,5 N E G 5 31,3 N E G
28 F 36 Pregnant Arg-Chaco Yes 9 32,1 N E G 4 30,8 N E G 2 12,5 N E G
29 M 59 cChHD Br-Piaui Yes 9 32,1 N E G 2 15,4 N E G 5 31,3 N E G
30 F 29 Mega-II Br-Go Yes 7 25,0 N E G 4 30,8 N E G 5 31,3 N E G
31 F NA Pregnant Par-Uk2 Yes 9 32,1 N E G 1 7,7 N E G 1 6,3 N E G
32 F 28 Pregnant Arg-Sg Yes 2 7,1 N E G 3 23,1 N E G 1 6,3 N E G
33 M 38 Routine Br-Go No 4 14,3 N E G 1 7,7 N E G 1 6,3 N E G
34 M 51 Routine Br-Uk Yes 5 17,9 N E G 1 7,7 N E G 1 6,3 N E G
35 M NA Blood donor Arg-BAs No 6 21,4 N E G 1 7,7 N E G 1 6,3 N E G
36 F 39 Routine Br-Go Yes 8 28,6 N E G 1 7,7 N E G 1 6,3 N E G
37 F 37 Routine Br-Go No 6 21,4 N E G 1 7,7 N E G 2 12,5 N E G
38 M NA Blood donor Arg-BA No 7 25,0 N E G 2 15,4 N E G 3 18,8 N E G
39 F 36 Routine Br-Bh Yes 7 25,0 N E G 4 30,8 N E G 3 18,8 N E G
40 F 40 Routine Br-Go Yes 8 28,6 N E G 4 30,8 N E G 5 31,3 N E G
41 F 40 Routine Br-Go Yes 9 32,1 N E G 6 46,2 N E G 5 31,3 N E G
42 F 58 Routine Br-Go Yes 11 39,3 N E G 6 46,2 N E G 6 37,5 N E G
Patients 1 to 32 are seropositive and 33 to 42 seronegative. 28 kDNA tests and 13 Sat DNA tests were performed for each sample.
kDNA, minicircle DNA; Sat-DNA, satellite DNA; GPM Good performing Methods in panels A and B; ID, sample identification number; G, Gender; Ag, age in years; EN,
Endemic precedence; %: Percentage of positive results; Cons, Consensus PCR result; F, female; M, male; NA, not available; 28 kDNA tests and 13 Sat DNA tests were
performed for each sample.
1T.cruzi DTU I,
2T.cruzi DTU II/V/VI, NE, not endemic; Uk, Unknown; Pos, positive consensus; Ind, indeterminate consensus; Neg, negative consensus; cChHD, chronic Chagas heart
disease, Mega Megacolon, CBBB, Complete Branch Bundle Blockage, HTx, Heart transplantation; Arg: Argentina; Bo: Bolivia; Br: Brazil; Par: Paraguay; BAs, Buenos Aires;
Bh, Bahia; Go, Goias; MG: Minas Gerais; Sg: Santiago del Estero.
doi:10.1371/journal.pntd.0000931.t003
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Table 4. Performance of PCR tests in comparison to consensus GPM reports and serodiagnosis.
Test PCR performance vs consensus GPM K+S PCR performance versus Serology
Lb/Test PCR Target Se Sp Acc kappa Se Sp Acc kappa BPM
N = 18 N = 20 N = 38 N = 38 N = 32 N = 10 N = 42 N = 38
LbA C K 33.3 60.0 47.4 20.1 31 70 40.5 0.0 N
LbB C K 72.2 35.0 52.6 0.1 66 30 57.1 0.0 N
LbC/1 C K 0.0 100.0 52.6 0.0 0 100 23.8 0.0 N
LbC/2 C S 66.7 15.0 39.5 20.2 69 10 54.8 20.2 N
Lb/D1 C K 94.4 45.0 68.4 0.4 81 40 71.4 0.2 N
Lb/D2 RT S 94.4 85.0 89.5 0.8 69 100 76.2 0.5 Y
Lb/D3 C S 94.4 85.0 89.5 0.8 63 100 71.4 0.4 Y
LbE C K 94.4 65.0 78.9 0.6 81 80 81.0 0.5 N
LbF/1 RT S 83.3 95.0 89.5 0.8 63 100 71.4 0.4 Y
LbF/2 RT K 72.2 90.0 81.6 0.6 53 90 61.9 0.3 N
LbG/1 RT K 100.0 60.0 78.9 0.6 84 60 78.6 0.5 N
LbG/2 RT K 100.0 65.0 81.6 0.6 78 40 69.0 0.4 N
LbG/3 RT K 100.0 65.0 81.6 0.6 78 40 69.0 0.4 N
LbG/4 RT S 94.4 90.0 92.1 0.8 63 60 61.9 0.4 N
LbH/1 C K 27.8 80.0 55.3 0.1 22 80 35.7 0.0 N
LbH/2 C K 22.2 80.0 52.6 0.0 16 80 31.0 0.0 N
LbI/1 C K 83.3 40.0 60.5 0.2 78 50 71.4 0.3 N
LbI/2 C K 38.9 40.0 39.5 20.2 53 40 50.0 20.1 N
LbJ C S 55.6 60.0 57.9 0.2 59 70 61.9 0.2 N
LbK/1 RT S 61.1 70.0 65.8 0.3 44 60 47.6 0.3 N
LbK/2 C K 0.0 100.0 52.6 0.0 0 100 23.8 0.0 N
LbL/1 C S 88.9 45.0 65.8 0.3 84 60 78.6 0.4 N
LbL/2 C S 83.3 60.0 71.1 0.4 72 60 69.0 0.3 N
LbM C K 66.7 50.0 57.9 0.2 59 50 57.1 0.1 N
LbN/1 C K 66.7 80.0 73.7 0.5 47 60 50.0 0.0 N
LbN/2 C S 72.2 80.0 76.3 0.5 47 70 52.4 0.1 N
LbO C K 66.7 55.0 60.5 0.2 47 30 42.9 20.2 N
LbP/1 C K 88.9 85.0 86.8 0.7 53 80 59.5 0.2 N
LbP/2 C K 11.1 100.0 57.9 0.1 6 100 28.6 0.0 N
LbQ C K 83.3 90.0 86.8 0.7 63 100 71.4 0.4 Y
LbR C K 88.9 55.0 71.1 0.4 81 70 78.6 0.5 N
LbS/2 RT S 50.0 90.0 71.1 0.4 38 100 52.4 0.2 N
LbS/4 C K 55.6 90.0 73.7 0.5 47 100 59.5 0.3 N
LbT RT K 50.0 75.0 63.2 0.3 41 80 50.0 0.1 N
LbU/1 C K 16.7 95.0 57.9 0.1 9 90 28.6 0.0 N
LbV/1 C K 27.8 100.0 65.8 0.3 16 100 35.7 0.1 N
LbV/2 C S 44.4 100.0 73.7 0.5 28 100 45.2 0.2 N
LbW C K 100.0 35.0 65.8 0.3 91 40 78.6 0.3 N
LbX C K 100.0 50.0 73.7 0.5 88 60 81.0 0.5 N
LbY C K 77.8 50.0 63.2 0.3 75 80 76.2 0.5 N
LbZ RT S 50.0 90.0 71.1 0.4 38 100 52.4 0.2 N
Median 72 77.5 68.4 0.4 59.4 70.0 59.5 0.2
(25-75p) (50–88.9) (55–90) (57.9–781) (0.2–0.6) (37.5–75) (60–100) (47.6–71.4) (0–0.4)
LbX/1-6, Laboratory and test identification; BPM, Best Performing Methods; Consensus GPM K + S: consensus findings of GPM by kDNA and Satellite DNA PCRs; C,
Conventional PCR, RT, Real Time PCR; K, kDNA; S, Satellite DNA; Se, sensitivity; Sp, specificity; Acc, accuracy; kappa, kappa index; N, negative; Y, affirmative; 25–75p, 25th-
75th percentiles; Bold type, Good Performing Methods (GPM) in sets A and B.
doi:10.1371/journal.pntd.0000931.t004
International PCR Study for T.cruzi Detection
www.plosntds.org 10 January 2011 | Volume 5 | Issue 1 | e931
Table 5. Intra-laboratory evaluation of best performing methods in human samples.
N6 Positive PCR/N6 tested samples
ID LbD2 LbD3 LbF1 LbQ % pos Cons
Seropositive samples 4 2/4 3/4 2/4 2/4 75 pos
6 4/4 4/4 4/4 4/4 100 pos
11 4/4 3/4 4/4 3/4 90,6 pos
15 2/4 3/4 3/4 3/4 59,4 pos
32 0/4 0/4 0/4 0/4 0 neg
Seronegative samples 33 0/4 0/4 0/4 0/4 0 neg
35 0/4 0/4 0/4 0/4 0 neg
38 0/4 0/4 0/4 0/4 0 neg
Concordance 28/32 29/32 29/32 28/32
ID, sample identification number; LbX/1-6, Laboratory and test identification; % pos, Percentage of Positivity; Cons, Consensus PCR Result; pos, positive; neg, negative.
doi:10.1371/journal.pntd.0000931.t005
Figure 2. Examples of the outputs of the four best performing PCR methods. A. LbD2 ; B.LbD3, C. LbF1 and D. LbQ. The methods are
described in Materials and Methods and Table 1. 6, 15: seropositive samples; 35; seronegative sample (Table 3). PC: Positive control: 10 fg/ml of T.cruzi
VI. NC. Negative Control: Master Mixes devoid of DNA.
doi:10.1371/journal.pntd.0000931.g002
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co-amplified simultaneously with the target sequence [50]. In a
PCR without an IAC, a negative result can indicate that the
reaction was inhibited, as a result of the presence of inhibitory
substances in the sample matrix. The presence of PCR inhibition
in Guanidine Hidrochloride-EDTA treated blood samples has
been described [22]. The European Standardization Committee
(CEN), in collaboration with International Standard Organization
(ISO) has proposed a general guideline for PCR testing that
requires the presence of IAC in the reaction mixture [51].
Therefore, only IAC-containing PCRs should undergo multicentre
collaborative trials, which is a prerequisite for validation.
Some other tests shown as GPM in sets A+B had very low
specificities (LbI2, LbW, LbG2, LbG3, Table 4). Amplicon carry-
over contamination is one of the most probable causes. PCR
master mixes with dUTP and Uracil-DNA N-glycosylase (UNG)
intended to abolish amplicon carry-over contamination were used
in some tests (LbF, LbG, LbL, LbS, Table 1). Nevertheless, some
of them did not show good specificity in set C (LbG2, LbG3,
LbG4, LbL1, LbL2, Table 4), suggesting that problems during
sample processing, such as sample to sample contamination could
have arisen. The median values of the sensitivities obtained in
testing the Set C samples with the 16 tests determined to be GPMs
by testing the Set A and Set B samples varied considerably
depending on the clinical characteristics of the persons from whom
the Set C samples were drawn. Indeed, sensitivity was 100% (25-
75p = 1002100) for immunosuppressed heart transplanted pts,
56.5% (25-75p = 39.1–66.3%) for asymptomatic and 57.1% (25-
75p = 14–75%) for symptomatic chronic Chagas disease patients.
These data point to the limitations of PCR strategies for diagnosis
of patients at the chronic phase of disease. In addition, some of
these samples had been stored at 4uC for at least two years before
this PCR study; thus higher PCR positivity might be obtained in
prospective clinical studies but it is unlikely that the current PCR
methods will have a sensitivity comparable to serological assays for
diagnosis of chronic Chagas disease.
The four BPM methods were transferred to the Coordinating
laboratory, where they were evaluated in a subset of clinical
samples, each one tested in four independent assays, obtaining
good concordance and confirming the performance reported by
the participating laboratories in the previous international study
(Tables 5 and 6). Further work is still needed to validate them
through prospective studies in different settings. In this regard, this
collaborative evaluation constitutes a starting point towards
technical improvement and development of an international
standard operating procedure (SOP) for T.cruzi PCR. In this
context, the BPMs could be recommended for alternative
diagnostic support, such as in the following settings: a) post-
treatment follow-up of patients to look for failure of therapy to
achieve parasitologic response [12,14–16,20,22]; b) diagnosis of
congenital Chagas disease in newborns in whom the presence of
maternal anti-T. cruzi antibodies make serological studies useless
[11,15,48]; c) early diagnosis of reactivation after organ trans-
plantation of T.cruzi infected recipients under immunosuppressive
therapy [18,41], d) differential diagnosis of Chagas reactivation in
patients with AIDS [39], and e) suspicion of oral transmission [52].
Moreover it can be useful for post-treatment follow-up of
experimental animals to look for failure of therapy to achieve
parasitologic cure [53]; in diagnosis in naturally infected
triatomines or triatomines used for xenodiagnosis, since it has
been shown that PCR tests are much more sensitive than
microscopic examination of intestinal contents [37,54]; and
diagnosis of T. cruzi infection in mammalian reservoirs for which
serologic tools have not been developed [38].
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